AviadoBio Announces Appointment of Jeff Goater as Chair of the Board o...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 18, 2024

RepTrak Announces 2024 Global RepTrak® 100 Report • Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disor • CF Industries Holdings, Inc. Declares Quarterly Dividend and Confirms Dates for First Quarter 2024 Results and Conference Call • WK Kellogg Co and Meijer Donate $50,000 to Battle Creek Public Schools Mission Tiger • First Annual U.S.-Ukraine Veterans' Charity Golf Tournament Announced with General Retired David Petraeus as Guest of Honor • Nationally Syndicated “The Bert Show” Hosts Candid Interview with Usher, Who Credits Top Morning-Drive Radio Intervi • Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Ti • Franklin Covey Announces New Common Share Purchase Plan • Yom HaAliyah: The International Fellowship of Christians and Jews Celebrates Helping Thousands of Jews Make Aliyah in 2023 • Canada brings the world together in pursuit of an ambitious global deal to end plastic pollution • Wheels in Motion: Nationwide Ride of a Life Time Cycling Event Set for April 27 to Support Children's Health • SuperWomen Of FMS Leadership Award Nominations Now Open • The UAE’s Largest Higher Education Institution, Higher Colleges of Technology, Selects YuJa Video Platform to Serve More t • Innovafeed Expands to U.S.; French Agtech Firm Opens Insect Innovation Center in Decatur, Ill. • Dr. Cathleen Brown Named Medical Director of Winona, Pioneering Menopause Telehealth Company • Sundial Media Group Extends Its Reach, Further Diversifying the Media Landscape • Angels Helpers NYC Announces 2024 Charity Gala “Big City, Big Hearts: New Yorkers Helping New Yorkers” • Dr. Laurie Leshin, Director of JPL, to Receive THE MUSES of the California Science Center Foundation 2024 Woman of the Year Awar • Semrush Holdings, Inc. Announces Investor Conference Call to Review First Quarter 2024 Financial Results • Bright Horizons Family Solutions Announces Date of First Quarter 2024 Earnings Release and Conference Call

AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors

LONDON , February 01 /Businesswire/ - AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today announced the appointment of Jeff Goater as Chair of the AviadoBio Board of Directors, effective immediately. Mr. Goater brings more than 20 years of biotech industry experience including gene therapy expertise to his role.

“Jeff is an experienced biotech executive with a proven track record of bringing much needed therapies into clinical development,” said Lisa Deschamps, Chief Executive Officer. “With his foundation as a research scientist, Jeff understands the potential impact gene therapies could have on people with neurodegenerative diseases. I look forward to working with him as we continue to advance the development of our gene therapies and delivery technology for frontotemporal dementia and amyotrophic lateral sclerosis.”

Currently, Mr. Goater serves as a Venture Partner at The Column Group and Interim CEO of Atavistik Bio. In his last position as CEO of Surface Oncology, he fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering, and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to his time at Surface, Mr. Goater served as Chief Financial Officer of Voyager Therapeutics where he was a member of the founding management team. Previously, he spent nearly a decade in investment banking, most recently as a Managing Director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry.

“I believe in the transformative potential of gene therapy to help those affected by devastating neurodegenerative diseases,” said Jeff Goater. “I am proud to join the AviadoBio team as we strive to apply a novel gene therapy in a way that targets the root cause of disease, bringing new delivery approaches to treating frontotemporal dementia and amyotrophic lateral sclerosis.”

Mr. Goater began his career as a research scientist in the field of AAV gene therapy and holds master’s degrees in microbiology/immunology, pathology, and business administration from the University of Rochester. Mr. Goater currently serves on the boards of Atavistik Bio, Judo Bio, Kallyope, Ribon Therapeutics and Surface Oncology.

About AviadoBio

AviadoBio’s mission is to develop and deliver potentially transformative gene therapies for people living with devastating neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Through a deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, AviadoBio is working relentlessly to overcome the challenges of delivering the right drug to the right place. Its innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases.

AviadoBio was founded on pioneering research from King’s College London and the UK Dementia Research Institute and has a leadership team with extensive gene therapy development, delivery and commercialization experience which uniquely positions the Company for success in bringing transformative medicines to patients.

AviadoBio’s investors include New Enterprise Associates (NEA), Monograph Capital, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Dementia Discovery Fund (DDF), Advent Life Sciences, EQT Lifesciences, and LifeArc.

For more information, please visit www.aviadobio.com and follow us at Twitter @AviadoBio and LinkedIn AviadoBio.